AI designed cancer drug gets FDA approval for clinical trials
/0 Comments/in Artificial Intelligence, Not PCa related/by MaxAnother AlphaFold evolution: Using AI to Identify Better Antibody Therapies
/0 Comments/in Artificial Intelligence, Not PCa related/by MaxAlphaFold keeps rocking: a new AI tool that can predict large proteins
/0 Comments/in Artificial Intelligence/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Early Results of Gedatolisib and Darolutamide in mCRPC Treatment July 4, 2025
- Mevrometostat Update: a New Phase 3 Trial for mCSPC July 1, 2025
- MDNA113 a Potentially Groundbreaking Immune Therapy for Solid Tumors Including mCRPC June 30, 2025
- Newsletter 26/2025 June 29, 2025